We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
+0.52%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$15.3B
AUM Growth
+$933M
(+6.5%)
Cap. Flow
+$1.09B
Cap. Flow
% of AUM
7.1%
Top 10 Holdings %
Top 10 Hldgs %
20.85%
Holding
1,816
New
17
Increased
573
Reduced
1,124
Closed
101
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$111M |
| 2 |
Amazon
AMZN
|
+$95.9M |
| 3 |
Microsoft
MSFT
|
+$91.8M |
| 4 |
Roper Technologies
ROP
|
+$69.8M |
| 5 |
PX
Praxair Inc
PX
|
+$68.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Brown-Forman Class B
BF.B
|
+$28.4M |
| 2 |
Becton Dickinson
BDX
|
+$28M |
| 3 |
W.W. Grainger
GWW
|
+$20.5M |
| 4 |
Lowe's Companies
LOW
|
+$15M |
| 5 |
Target
TGT
|
+$10.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.5% |
| 2 | Financials | 13.66% |
| 3 | Healthcare | 12.92% |
| 4 | Consumer Discretionary | 10.42% |
| 5 | Industrials | 10.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
Sarepta Therapeutics
SRPT
$1.66B
| $2.79M | 0.02% |
37,696
-6,198
| -14% | -$413K |
|
552
United Therapeutics
UTHR
$26.3B
| $2.78M | 0.02% |
24,769
-3,426
| -12% | -$435K |
|
|
HES
553
DELISTED
Hess
HES
| $2.78M | 0.02% |
54,889
-8,843
| -14% | -$433K |
|
554
Ralph Lauren
RL
$22.2B
| $2.74M | 0.02% |
24,502
+1,280
| +6% | +$139K |
|
555
Navient
NAVI
$774M
| $2.72M | 0.02% |
207,521
+8,045
| +4% | +$109K |
|
556
Jones Lang LaSalle
JLL
$15.1B
| $2.72M | 0.02% |
15,580
-318
| -2% | -$51.1K |
|
557
Avery Dennison
AVY
$12.3B
| $2.72M | 0.02% |
25,604
-1,464
| -5% | -$170K |
|
558
Labcorp
LH
$24.3B
| $2.7M | 0.02% |
19,431
+474
| +3% | +$69.6K |
|
559
Ionis Pharmaceuticals
IONS
$9.35B
| $2.7M | 0.02% |
61,179
-9,419
| -13% | -$479K |
|
560
Camden Property Trust
CPT
$11.3B
| $2.68M | 0.02% |
31,799
-664
| -2% | -$55.5K |
|
561
F5
FFIV
$22.1B
| $2.64M | 0.02% |
18,284
+1,233
| +7% | +$177K |
|
562
EQT Corp
EQT
$33.2B
| $2.64M | 0.02% |
101,948
+9,646
| +10% | +$277K |
|
563
TechnipFMC
FTI
$30.6B
| $2.63M | 0.02% |
120,086
-48,341
| -29% | -$1.12M |
|
564
Warner Bros
WBD
$64.6B
| $2.6M | 0.02% |
121,086
-8,197
| -6% | -$195K |
|
565
Xylem
XYL
$28.5B
| $2.59M | 0.02% |
33,651
+8,489
| +34% | +$628K |
|
566
Global Payments
GPN
$22.1B
| $2.56M | 0.02% |
22,977
+749
| +3% | +$82.8K |
|
567
Waters Corp
WAT
$36.8B
| $2.56M | 0.02% |
12,893
+201
| +2% | +$41.6K |
|
568
Textron
TXT
$16.6B
| $2.55M | 0.02% |
43,272
+828
| +2% | +$48.7K |
|
|
PARA
569
DELISTED
Paramount Global Class B
PARA
| $2.55M | 0.02% |
49,558
-375
| -0.8% | -$20.6K |
|
|
AVXS
570
DELISTED
AveXis, Inc. Common Stock
AVXS
| $2.54M | 0.02% |
20,571
-306
| -1% | -$36.4K |
|
571
Masco
MAS
$16B
| $2.53M | 0.02% |
62,518
+2,655
| +4% | +$114K |
|
572
PetMed Express
PETS
$42.5M
| $2.51M | 0.02% |
60,136
+47,471
| +375% | +$2.19M |
|
573
FMC
FMC
$1.42B
| $2.5M | 0.02% |
37,716
+2,016
| +6% | +$150K |
|
574
Wayfair
W
$11.1B
| $2.43M | 0.02% |
35,953
+26,682
| +288% | +$2.24M |
|
|
ANSS
575
DELISTED
Ansys
ANSS
| $2.43M | 0.02% |
15,490
+679
| +5% | +$109K |
|
Similar funds
ProShare Advisors's Q1 2018 Portfolio in Review
As of Q1 2018, ProShare Advisors held 1,816 positions worth $15.3B, up 6.5% from $14.4B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
ProShare Advisors deployed $1.09B of net new capital in Q1 2018, opening 17 new positions and adding to 573 existing holdings. Its largest new stake was CoStar Group: 93,260 shares worth $3.38M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Brown-Forman Class B, an estimated $28.4M trimmed.
- ProShare Advisors's largest Q1 2018 buy was CoStar Group: 93,260 shares worth $3.38M.
- ProShare Advisors added most to Apple in Q1 2018, an estimated $111M increase.
- ProShare Advisors's biggest Q1 2018 reduction was Brown-Forman Class B, cutting an estimated $28.4M.
- ProShare Advisors fully exited Bioverativ Inc. Common Stock in Q1 2018, selling an estimated $3.8M.
- ProShare Advisors's ten largest holdings make up 21% of its $15.3B portfolio in Q1 2018.
- ProShare Advisors opened 17 new positions and closed 101 in Q1 2018.
- ProShare Advisors's portfolio value rose 6.5% quarter-over-quarter to $15.3B.
Based on ProShare Advisors's 13F filing for Q1 2018, filed 14 May 2018.